Capricor Therapeutics announces promising long-term results for deramiocel deramiocel in Duchenne muscular dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared encouraging three-year safety and efficacy results from ... Read More
Pfizer’s CIFFREO Phase 3 study in DMD fails to meet primary endpoint
Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study did not meet its primary endpoint. The ... Read More
Pfizer ends clinical Trials of DMD drug domagrozumab after disappointing results
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy ... Read More
Exonics Therapeutics receives $5m seed funding to advance Duchenne Muscular Dystrophy therapy
Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne ... Read More